Rituximab(利妥昔单抗)市场:现状分析与预测(2023-2030年)

由于非霍奇金淋巴瘤患病率不断上升，预计利妥昔单抗市场在预测期内将以 16% 的复合年增长率增长。非霍奇金淋巴瘤 (NHL) 在美国是一种相对常见的癌症，约占所有癌症患者的 4%。截至 2022 年 3 月，美国癌症协会估计大约有 80,470 人，包括成人和儿童，将被诊断患有非霍奇金淋巴瘤。据估计，男性终生罹患非霍奇金淋巴瘤的风险为 42 分之一，女性为 52 分之一，这可能是由于目标人群不断增加。

为了更好地了解利妥昔单抗行业的市场采用情况，市场包括北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区）、亚太地区（中国） 、日本、印度）。、亚太地区其他地区）和世界其他地区是根据其在世界其他地区的存在情况进行分析的。北美占据市场主导占有率，预计在预测期内将继续如此。北美的医疗保健设施具有最高标准，并且由于有利的政策而可供大量人口使用，这使得许多人能够负担得起（即使不是不存在）医疗保健。此外，北美地区几个发达国家人口中非霍奇金淋巴瘤患病率的增加、人口老龄化、技术进步以及医疗保健支出的增加是推动市场增长的主要因素。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提

• 调查流程
• 调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 全球Rituximab市场上新型冠状病毒感染疾病(COVID-19)的影响

第6章 全球Rituximab市场收益，2020-2030年

第7章 市场洞察:各给药途径

• 皮下
• 静脉内
• 非口服

第8章 市场洞察:各用途

• 非何杰金氏淋巴瘤
• 慢性淋巴性白血病
• 类风湿性关节炎
• 其他

第9章 市场洞察:各流通管道

• 医院药局
• 线上药局
• 其他

第10章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第11章 Rituximab市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 Rituximab市场机会

第13章 Rituximab市场趋势

第14章 需求面和供给面的分析

• 需求面分析
• 供给面分析

第15章 价值链分析

第16章 价格分析

第17章 竞争模式

• 波特的五力分析
• 竞争情形

第18章 企业简介

• Pfizer Inc.
• Amgen Inc.
• Viatris Inc.
• F. Hoffmann-La Roche
• Dr. Reddy's Laboratories Ltd.
• Zydus Group
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Hetero
• BioXpress Therapeutics SA

第19章 免责声明

Rituximab is a type of antibody therapy that can be used in combination with chemotherapy or alone to target cancer cells by attaching to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. It can be used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and other blood vessel diseases such as granulomatosis with polyangiitis and microscopic polyangiitis by slowing or stopping the growth of cancer cells and decreasing joint pain and swelling.

The Rituximab Market is expected to grow at a strong CAGR of 16% during the forecast period owing to the rising prevalence of non-hodgkin lymphoma. In the US, non-Hodgkin lymphoma (NHL) is a relatively common cancer that affects approximately 4% of all cancer cases. As of March 2022, the American Cancer Society estimates that approximately 80,470 people, including both adults and children, will be diagnosed with NHL. The lifetime risk of developing NHL is estimated to be 1 in 42 for men and 1 in 52 for women, indicating that the growth of the target population is likely to contribute to a growth.

Based on the route of administration, the market is segmented into subcutaneous, intravenous, and parenteral. The intravenous (IV) category held a significant share of the market in 2022 as IV rituximab is administered through a vein, making it a quick and efficient way to deliver the drug to the patient's body. Moreover, IV rituximab is absorbed into the bloodstream quickly, allowing it to begin working faster than other forms of rituximab. Thus, these factors are driving the growth of the segment in the forecast period.

By application, the market is categorized into non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. The non-hodgkin lymphoma is anticipated to grow with significant CAGR during the forecast period. According to the World Health Organization, an estimated 5,000,000 new cases of non-Hodgkin's lymphoma (NHL) were diagnosed in 2020. In the United States, NHL accounts for nearly 4% of all cancer cases. The rising incidence of NHL is expected to drive significant demand for rituximab biosimilars in the market over the forecast period.

Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and others. The hospital pharmacy held a dominant share of the market in 2022 owing to the increasing patient population, and growing focus on patient safety. Moreover, as the number of prescriptions filled by hospitals continues to rise, so too will the demand for hospital pharmacies to manage and dispense these medications, thus having a positive impact on the segmental growth.

For a better understanding of the market adoption of the rituximab industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the dominant share of the market and is expected to do so even in the forecast period. The healthcare facilities in North America are of the highest standards and are accessible to the large population because of favorable policies making healthcare affordable to many if not all. Moreover, the increasing incidence of non-hodgkin lymphoma cases among the population, the aging population, technological advancements, and increasing healthcare spending in several developed nations of North America region are the major factors driving the growth of the market.

Some of the major players operating in the market include: Pfizer Inc.; Amgen Inc.; Viatris Inc.; F. Hoffmann-La Roche ; Dr. Reddy's Laboratories Ltd.; Zydus Group; Novartis AG; Teva Pharmaceutical Industries Ltd.; Hetero; and BioXpress Therapeutics SA.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Rituximab Market
• 2.2. Research Methodology of the Rituximab Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL RITUXIMAB MARKET COVID-19 IMPACT

6 GLOBAL RITUXIMAB MARKET REVENUE, 2020-2030F

7 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 7.1. Subcutaneous
• 7.2. Intravenous
• 7.3. Parenteral

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Non-Hodgkin Lymphoma
• 8.2. Chronic Lymphocytic Leukemia
• 8.3. Rheumatoid Arthritis
• 8.4. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospitals Pharmacy
• 9.2. Online Pharmacy
• 9.3. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. United States
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. France
  • 10.2.3. U.K.
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia Pacific
• 10.4. Rest of World

11 RITUXIMAB MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 RITUXIMAB MARKET OPPORTUNITIES

13 RITUXIMAB MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICE ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Porter's Five Forces Analysis
• 17.2. Competitive Landscape

18 COMPANY PROFILED

• 18.1. Pfizer Inc.
• 18.2. Amgen Inc.
• 18.3. Viatris Inc.
• 18.4. F. Hoffmann-La Roche
• 18.5. Dr. Reddy's Laboratories Ltd.
• 18.6. Zydus Group
• 18.7. Novartis AG
• 18.8. Teva Pharmaceutical Industries Ltd.
• 18.9. Hetero
• 18.10. BioXpress Therapeutics SA

19 DISCLAIMER